Literature DB >> 874787

Determination of triprolidine in human plasma by quantitative TLC.

R L DeAngelis, M F Kearney, R M Welch.   

Abstract

A chromatographic thin-layer fluorescence procedure, with a sensitivity limit of 0.8 ng/ml, is described for the quantitative analysis of triprolidine in human and rat plasma. Following the intravenous administration of 1 mg/kg of triprolidine to rats, the drug distributed rapidly into tissues and was eliminated from plasma with a half-life of 53 min. The method was used to determine the plasma triprolidine levels in 16 normal human volunteers following oral administration of 3.75 mg of triprolidine hydrochloride in 15 ml of a syrup. The drug obtained a mean peak plasma level of 8.2 ng/ml in 2 hr and was eliminated from the plasma with a half-life of 5 hr. Considerable individual variation was observed in the area under the plasma triprolidine level-time curve; values ranged from 19 to 163 ng hr/ml with a mean value of 75 ng hr/ml.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874787     DOI: 10.1002/jps.2600660627

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration.

Authors:  D M Cocchetto; W A Wargin; J W Crow
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

Review 2.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

3.  Pharmacodynamic and pharmacokinetics of BW 825C: a new antihistamine.

Authors:  A F Cohen; M J Hamilton; S H Liao; J W Findlay; A W Peck
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers.

Authors:  Salvatore Febbraro; Tim Shea; Ana Santos Cravo
Journal:  Clin Pharmacol Drug Dev       Date:  2020-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.